Defibrotide in the COVID-19 coagulopathy: What is the timing?

J Thromb Haemost. 2020 Nov;18(11):3113-3115. doi: 10.1111/jth.15100.

Authors

Antonio Macciò¹, Clelia Madeddu², Giovanni Caocci^{3

4}, Sara Oppi⁴, Giorgio La Nasa^{3

4}

Affiliations

¹ Department of Gynecologic Oncology, Businco Hospital, Azienda Ospedaliera Brotzu, Cagliari, Italy.
² Department of Medical Sciences and Public Health, Medical Oncology Unit, University of Cagliari, Cagliari, Italy.
³ Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
⁴ Hematology and Transplant Center, Businco Hospital, Azienda Ospedaliera Brotzu, Cagliari, Italy.

No abstract available

Keywords: COVID-19; coagulopathy; defibrotide; resistance; tolerance.

Publication types

Letter
Comment

MeSH terms

Blood Coagulation Disorders* / drug therapy
COVID-19*
Fibrinolytic Agents / therapeutic use
Humans
Pandemics
Polydeoxyribonucleotides
SARS-CoV-2

Substances

Fibrinolytic Agents
Polydeoxyribonucleotides
defibrotide